High efficiency is key in applications such as data centers, and new standards codify the now-mandatory requirements.
Pharmaceutical company Johnson & Johnson announced new late-breaking results from its Phase 2 JASMINE study showing that investigational therapy nipocalimab significantly reduced disease activity in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results